Please use this identifier to cite or link to this item:
http://dspace.lamu.edu.zm:8080/handle/123456789/2898Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Sialubanje, Cephas | - |
| dc.contributor.author | Kapina, Muzala | - |
| dc.contributor.author | Chewe, Orbrie | - |
| dc.contributor.author | Matapo, Belem Blamwell | - |
| dc.contributor.author | Ngomah, Albertina Moraes | - |
| dc.contributor.author | Gianetti, Brittany | - |
| dc.contributor.author | Ngosa, William | - |
| dc.contributor.author | Kasonde, Mpanga | - |
| dc.contributor.author | Musonda, Kunda | - |
| dc.contributor.author | Mulenga, Modest | - |
| dc.contributor.author | C, Michelo | - |
| dc.contributor.author | Sinyange, Nyambe | - |
| dc.contributor.author | Bobo, Patricia | - |
| dc.contributor.author | Zyambo, Khozya | - |
| dc.contributor.author | Mazyanga, Lucy | - |
| dc.contributor.author | Bakyaita, Nathan | - |
| dc.contributor.author | Mukonka, Victor M | - |
| dc.date.accessioned | 2023-02-06T14:59:05Z | - |
| dc.date.available | 2023-02-06T14:59:05Z | - |
| dc.date.issued | 2022-10-21 | - |
| dc.identifier.citation | Sialubanje C, Kapina M, Chewe O, et al. Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia. BMJ Open 2022;12:e066945. doi:10.1136/ bmjopen-2022-066945 | en_US |
| dc.identifier.uri | http://dx.doi. org/10.1136/bmjopen-2022- 066945 | - |
| dc.identifier.uri | http://155.0.177.102:8080/jspui//xmlui/handle/123456789/2898 | - |
| dc.description | This Journal article can be found at this cite:http://dx.doi. org/10.1136/bmjopen-2022- 066945 | en_US |
| dc.description.abstract | Zambia experienced a major cholera outbreak in 2017–2018, with more than 5905 cases reported countrywide, predominantly from the peri-urban slums of Lusaka city. The WHO recommends the use of oral cholera vaccines (OCVs) together with traditional control measures, including health promotion, provision of safe water and improving sanitation, in cholera endemic areas and during cholera outbreaks. In response to this outbreak, the Zambian government implemented the OVC campaign and administered the Euvichol-plus vaccine in the high-risk subdistricts of Lusaka. Although OCVs have been shown to be effective in preventing cholera infection in cholera endemic and outbreak settings, the effectiveness of the Euvichol-plus vaccine has not yet been evaluated in Zambia. This study aimed to determine the effectiveness of two doses of OCV administered during the 2017/2018 vaccination campaign. | en_US |
| dc.description.sponsorship | Ministry of Health and WHO. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ | en_US |
| dc.subject | Euvichol-plus vaccine | en_US |
| dc.subject | cholera vaccine | en_US |
| dc.subject | Lusaka | en_US |
| dc.subject | Zambia | en_US |
| dc.subject | Outbreak | en_US |
| dc.title | Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case– control study in Lusaka, Zambia | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Internal Medicine | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Effectiveness_of_two_doses_of_Euvichol-plus_oral_c MMPubs.pdf | Modest Mulenga Cholera | 508.96 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.